panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 377
- Registration Number
- NCT01412957
- Locations
- 🇷🇸
Research Site, Sremska Kamenica, Serbia
Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
- Target Recruit Count
- 140
- Registration Number
- NCT01388621
- Locations
- 🇩🇪
Stauferklinikum Schwäbisch Gmünd, Mutlangen, Baden Württemberg, Germany
🇩🇪Praxis Dr. Oettle, Friedrichshafen, Baden-Württemberg, Germany
🇩🇪Carl-Thiem-Klinikum Cottbus Frauenklinik, Cottbus, Brandenburg, Germany
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- PD Dr. med. Volker Heinemann
- Target Recruit Count
- 111
- Registration Number
- NCT01384994
- Locations
- 🇩🇪
Ludwig-Maximilians - University of Munich, Munich, Germany
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01312857
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
- Conditions
- First Posted Date
- 2011-03-10
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT01312493
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 31
- Registration Number
- NCT01308840
- Locations
- 🇺🇸
Dana-Farber / Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
- Conditions
- Interventions
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Neal Ready
- Target Recruit Count
- 6
- Registration Number
- NCT01305772
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)
- Conditions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
- Target Recruit Count
- 59
- Registration Number
- NCT01257360
- Locations
- 🇩🇪
Tagestherapiezentrum am ITM & III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
🇩🇪Prosper Hospital Medizinische Klinik I, Recklinghausen, Germany
🇩🇪Klinikum Esslingen Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin, Esslingen, Germany
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
- Conditions
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01226719
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT01215539
- Locations
- 🇬🇷
General Hospital of Athens "Hippokratio", 2nd Dept of Internal Medicine, Athens, Greece
🇬🇷Rio University Hospital, Dept of Oncology, Patras, Greece
🇬🇷Hygeia Hospital, 3rd Dept of Medical Oncology, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.